TA
Take Ltd (TAKE)
₹13.69
Mkt cap
₹192 Cr
P/E ratio
22.00
P/B
5.90
Div yield
0.00%
ROE
16.50%
ROCE
18.50%
EPS (TTM)
₹0.62
Book value
₹2
52W range
10–50
Sector
Healthcare
Price history
Previous close
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services [1]
NSE TAKEBSE 532890
Health check
Mixed
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsBearish
52-week range
−72.70% from high₹14
₹10+38.56% from low₹50
Current
₹13.69
Prev close
₹13.04
Day
+4.98%
Price performance
1D
+4.98%
1W
+5.39%
1M
+19.04%
3M
−37.32%
6M
−51.35%
1Y
−52.50%
YTD
−66.21%
Financials
Revenue, profit & margin
P/E ratio
22.0×
TAKE is 17% below the sector median of 26.4×
TAKE22.0×
Sector median26.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.19 | 30.37 | 29.42 | |
| YoY Sales growth | -99.88% | -100.00% | -100.00% | -100.00% | -100.00% | |||||||||
| Expenses | 1.50 | 1.98 | 15.76 | 2.22 | 0.90 | 2.89 | 1.15 | 0.44 | 0.30 | 0.35 | 55.01 | 30.64 | 27.65 | |
| Operating Profit | -1.45 | -1.98 | -15.76 | -2.22 | -0.90 | -2.89 | -1.15 | -0.44 | -0.30 | -0.35 | -0.82 | -0.27 | 1.77 | |
| OPM % | -2,900.00% | -1.51% | -0.89% | 6.02% | ||||||||||
| Other Income | 0.41 | 4.07 | -93.70 | -0.97 | -0.23 | 51.31 | -3.48 | -0.29 | 6.92 | 1.46 | 5.18 | 1.33 | 0.44 | |
| Interest | 0.56 | 0.54 | 0.54 | 0.49 | 0.50 | 0.73 | 0.24 | 0.18 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation | 0.30 | 0.11 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit before tax | -1.90 | 1.44 | -110.01 | -3.69 | -1.64 | 47.68 | -4.88 | -0.91 | 6.45 | 1.11 | 4.36 | 1.06 | 2.21 | |
| Tax % | -18.42% | 248.61% | 0.55% | 1.63% | -3.66% | 0.00% | 0.00% | 0.00% | 2.48% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -1.55 | -2.14 | -110.61 | -3.75 | -1.58 | 47.68 | -4.88 | -0.91 | 6.29 | 1.11 | 4.36 | 1.06 | 2.21 | |
| EPS in Rs | -0.10 | -0.14 | -7.48 | -0.25 | -0.11 | 3.22 | -0.33 | -0.06 | 0.43 | 0.08 | 0.29 | 0.07 | 0.15 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 20260.00%Promoter
Promoters0.00%
FIIs0.21%
DIIs0.00%
Public99.79%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹444.30 | 67.46 | 17,935 | 0.28% | 32 | −45.17% | 833 | −8.55% | 9.99% |
| Indegene | ₹666.20 | 37.64 | 16,055 | 0.34% | 112 | +9.99% | 1,122 | +39.55% | 18.82% |
| Suven Life Scie. | ₹277.80 | — | 7,850 | 0.00% | −107 | −38.33% | 1 | +30.43% | −79.54% |
| Vimta Labs | ₹498.90 | 27.37 | 2,230 | 0.40% | 21 | +3.46% | 112 | +9.95% | 25.23% |
| Fabtech Tech. | ₹139.78 | 20.87 | 621 | 0.43% | 15 | −67.06% | 92 | −24.19% | 13.88% |
| Novelix Pharma. | ₹70.05 | 42.89 | 199 | 0.00% | 2 | +194.34% | 45 | +23.02% | 10.87% |
| Bilcare | ₹84.43 | 5.46 | 199 | 0.00% | 1 | +175.74% | 248 | +39.41% | 7.06% |
| Take | ₹12.99 | 21.99 | 192 | 0.00% | 2 | +450.79% | 29 | — | 18.52% |
| Median: 9 Co. | ₹139.78 | 26.38 | 621 | 0.00% | 3 | +9.99% | 92 | +26.73% | 10.87% |
Filings
Annual reports15
Concall transcripts22
TranscriptAug 2021TranscriptJun 2021TranscriptFeb 2021TranscriptDec 2020TranscriptSep 2020TranscriptOct 2019TranscriptAug 2019TranscriptMay 2019TranscriptMar 2019TranscriptFeb 2019TranscriptFeb 2019TranscriptAug 2018TranscriptMay 2018TranscriptFeb 2018TranscriptNov 2017TranscriptNov 2017TranscriptAug 2017TranscriptMay 2017TranscriptJan 2017TranscriptDec 2016TranscriptOct 2016PPTFeb 2016
Credit ratings4
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 13 Nov - TAKE Limited reports H1 FY27 income of ₹615.54 million, PAT ₹32.75 million; launches TAKE.Health and ₹50 million innovation fund.Board Meeting Outcome for Outcome Of The Board Meetine Held On Friday. November 13. 2026 13 Nov - Board approved Q2 and H1 FY27 results; consolidated income Rs615.54 million, PAT Rs32.75 million.Financial Results For Quarter And Half Year Ended September 30, 2026 13 NovBoard Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company. 5 Nov - Board to meet on November 13, 2026 to approve Q2 and half-year FY2026-27 financial results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 14 Oct - TAKE Limited filed Regulation 74(5) certificate for quarter ended September 30, 2026.


